t*******o
发帖数: 1464 | 1 关键词FDA meeting "early June"
Whether or not MannKind can use that data for the Dreamboat device in their
resubmission to the FDA will be clarified in a face to face meeting with the
FDA in ‘early June.’ If that meeting goes as MannKind expects, they will
file their resubmission within a few weeks after. According to MannKind, at
least two potential Big Pharma partners have been helping them with
preparations for that face to face meeting. |
|
t*******o
发帖数: 1464 | 2 5/21
Interesting Options Volume for MannKind Corporation (MNKD)
NEW YORK (Market Intellisearch) -- MNKD options saw interesting call
activity today. A total of 1,967 put and 8,881 call contracts were traded
raising a low Put/Call volume alert. Today's traded Put/Call ratio is 0.22.
There were 4.51 calls traded for each put contract.
Options can be used as predictors of stock behavior. Investors can use Put/
Call ratios as technical indicators to read for signs of institutional
sentiment. The Put... 阅读全帖 |
|
|
|
f**********g
发帖数: 2252 | 5 来自主题: _Stockcafeteria版 - MNKD MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
|
f**********g
发帖数: 2252 | 7 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
f**********g
发帖数: 2252 | 8 MannKind Says FDA Review Of Afrezza To Take Four More Weeks
0 minutes ago - Dow Jones News
Related Companies
Symbol Last %Chg
MNKD 7.97 0.00%
As of 4:00 PM ET 12/27/10
DOW JONES NEWSWIRES
MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of
its new drug application for its inhaled-insulin product for diabetics will
require four additional weeks.
The biopharmaceutical company, which has no products on the market currently
, had been expecting FDA approval of Afrezza by Wed... 阅读全帖 |
|
w**a
发帖数: 3510 | 9 Top Picks Update
MannKind (MNKD 1.32)
From Nate’s Notes
Though shares of MannKind (MNKD) have continued to struggle following a
reverse split that was carried out back in March, the company's lead
product, Afrezza (an inhaled form of insulin for both Type-1 and Type-2
diabetics) is continuing to win high praises and gain converts among the
small number of patients who have actually heard about it so far.
Up until this point, the company has done virtually no advertising of the
product, but this ... 阅读全帖 |
|
j*****7
发帖数: 4348 | 10 From cholesterol fighters to asthma relief, these treatments could earn Big
Pharma $170 billion
By Mike Tarsala | 24/7 Wall St.
Jul 22, 2009 | Updated: 12:29 p.m. ET Jul 22, 2009
Safety and efficacy data are critical to drug candidates. But what really
makes a potential drug attractive is strong top-line data, a new biotech-
based treatment, and a massive potential market.
With help from Thomson Reuters' SD Pharma database and our own backlog of
coverage, BioHealthInvestor.com, a 247wallst.com ... 阅读全帖 |
|
|
|
h*******o
发帖数: 4884 | 13 I don't think there is any oral insulin on the market. A bunch of them are
under clinical trial
You might wanna try inhalation.
Afrezza (an fast acting inhale insulin drug) from Mannkind is expecting an
FDA approval in the coming months. |
|
j********y
发帖数: 3 | 14 有个我关注的股票
MannKind Corporation (Public, NASDAQ:MNKD)
这个股票最近3天每天在盘中有个0.5M的交易，但交易后，既不大涨，又不大跌。
这个是什么？是庄之间的倒手吗?
有人清楚吗？ |
|
o****r
发帖数: 132 | 15 IB可以。
Name MannKind Corp
Number of Lenders with Inventory 10
Symbol @ Exchange MNKD @ ARCA
ISIN Code US56400P2011
CUSIP 56400P201
Country United States
Quantity
Available 550'000 shares
Current
Indicative Rate -92.149
有30WB送上. 很容易查. 你可以发短信给我. |
|
O**I
发帖数: 776 | 16 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
w****r
发帖数: 245 | 17 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
k********8
发帖数: 7948 | 18 WSJ by By KAREN JOHNSON
当年25岁的Francis Chou还是一名加拿大的电话修理工，他和6位同事一起凑了5万1千
加元，办起了一个投资俱乐部。
31年过去了。如今Chou为他的投资者们管理着超过6.5亿美元的资产，他的公司Chou
Associates Management是北美表现最好的债券基金。
回忆起他的股票投资俱乐部，Chou说：“尽管投资额不大，但是当时的收益还不错。”
确实是这样的，Chou当初的同事和其他在早期投资的家人朋友现在身家都超过了200万
美元。
Chou从底层做起的轨迹向世界展示了投资者如何运用“试错法”（不断在实验和错误中
提高）来提高收益并且打败长期偏低的利率。在刚开始时，Chou只投资股票，和巴菲特
一样，他采用的是经典的价值投资法。
在他朴素的郊区办公室中，Chou告诉记者：“投资的关键是要找到有价值的便宜股票。”
56岁的Chou天生就是一个找便宜货的好手。他的父母是中国人，而他则出生在印度。幼
年的他帮助母亲完成采购任务，时常在印度北部城市阿拉哈巴德的食物商店间穿梭。
Chou在1976年追随他的哥哥来到加拿大，在做电话... 阅读全帖 |
|
|
|
|
q********g
发帖数: 10694 | 22 大家可以看看有多少股是股版的热门股：FIT，SCTY，MNKD，AMBA，LL，GPRO
PPC也算是。
Short Interest部分表达了FA里的负面因素。散户不应该一厢情愿地等待short
squeezing。正如以前哥说过GPRO：59买的可以全身而退，25买的不一定能活着回来。
没有纯TA，TA是FA的表达，正确与否，合理与否，取决于市场。但是好的FA最终一定会
用好的TA来表达，反之则不然。
Ticker Company Exchange ShortInt Float Outstd Industry
INSY Insys Therapeutics Inc Nasdaq 85.67% 24.18M 71.85M
Biotechnology & Drugs
PPC Pilgrim's Pride Corporation Nasdaq 65.75% 59.32M 255
.15M Food Processing
AAC AAC Holdin... 阅读全帖 |
|
|
h*******o
发帖数: 4884 | 24 I don't think there is any oral insulin on the market. A bunch of them are
under clinical trial
You might wanna try inhalation.
Afrezza (an fast acting inhale insulin drug) from Mannkind is expecting an
FDA approval in the coming months. |
|
|
|
|
w***y
发帖数: 2537 | 28 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ER for week August 2-6
发信站: BBS 未名空间站 (Sun Aug 1 22:47:17 2010, 美东)
Monday, Aug. 2
10 a.m.: ISM Manufacturing index on business activity in July, released by
the Institute for Supply Management.
10:15 a.m. Federal Reserve Chairman Ben Bernanke speaking on "challenges for
the economy and state governments."
4 p.m. Treasury Secretary Timothy Geithner speaking on the next steps for
financial reform.
Tuesday, Aug. 3
8:30 a.m.: P... 阅读全帖 |
|
K********g
发帖数: 9389 | 29 The per share purchase price of the shares sold to Seaside 88 will be at an
8% discount to the volume weighted average trading price of MannKind common
stock for the ten consecutive trading days immediately preceding each
closing date (the "VWAP"). For any closing to take place, the VWAP must be
at least $6.50 per share.
我的娘也，跌不下去了。 6.5上了保险，他奶奶的 |
|
f**********g
发帖数: 2252 | 30 CEO好像很看好，买了很多。
http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
Mann, Alfred E
Purchase
1/11/2011
-0.04% 700.0K
$6.1M $8.71 - $8.71 50,848,400
Purchase
12/29/2010
-0.04% 700.0K
$5.8M $8.22 - $8.22 50,148,400
Purchase
12/15/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
12/14/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
10/20/2010
-0.04% 700.0K
$5.0M $7.15 - $7.15 48,748,400 |
|
f**********g
发帖数: 2252 | 31 CEO好像很看好，买了很多。
http://www.marketwatch.com/story/mannkind-ceo-bets-big-on-diabe
Mann, Alfred E
Purchase
1/11/2011
-0.04% 700.0K
$6.1M $8.71 - $8.71 50,848,400
Purchase
12/29/2010
-0.04% 700.0K
$5.8M $8.22 - $8.22 50,148,400
Purchase
12/15/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
12/14/2010
-0.04% 700.0K
$5.9M $8.46 - $8.46 49,448,400
Purchase
10/20/2010
-0.04% 700.0K
$5.0M $7.15 - $7.15 48,748,400 |
|
O**I
发帖数: 776 | 32 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 33 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
v**********m
发帖数: 5516 | 34 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
v**********m
发帖数: 5516 | 35 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
f**********g
发帖数: 2252 | 36 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
f**********g
发帖数: 2252 | 37 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
w*******0
发帖数: 13 | 38 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 39 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 40 这篇文章不错, 刚稀释过,钱还够烧一阵.看图形也不错,盘小,可以少量埋伏.
请生物专家们补充.
http://finviz.com/screener.ashx?v=341&t=ALXA
Alexa Pharmaceuticals (ALXA) Market Cap $102.4 Million 05/13/11 at 1.42 PPS
Alexa received its CRL on October 11, 2010 for its lead product, AZ-004, for
reducing agitation in patients with schizophrenia or bipolar disorder. The
active ingredient in their Staccato device that emits an aerosol spray to be
inhaled by the patient is loxapine, a drug already approved for use as an
antipsychotic medication. Th... 阅读全帖 |
|
v**********m
发帖数: 5516 | 41 http://seekingalpha.com/article/270094-biotech-some-crl-recipie
Alexa Pharmaceuticals (ALXA) Market Cap $102.4 Million 05/13/11 at 1.42 PPS
Alexa received its CRL on October 11, 2010 for its lead product, AZ-004, for
reducing agitation in patients with schizophrenia or bipolar disorder. The
active ingredient in their Staccato device that emits an aerosol spray to be
inhaled by the patient is loxapine, a drug already approved for use as an
antipsychotic medication. The two Phase III trials leadin... 阅读全帖 |
|
t******g
发帖数: 462 | 42 Thanks.
ALXA 如何? 马上12号有个FDA panel, 好象不是很positive
http://seekingalpha.com/article/311279-5-healthcare-companies-w
A few days later Alexza's (ALXA) Adasuve is slated to face the FDA's Advisory Committee. Adasuve was rejected in October 2010 (under the name AZ-004) citing adverse pulmonary reactions as well as a required human factors study to validate the product can be used successfully. Alexza states these issues are resolved, but the Advisory Committee has stated it will focus on pulmonary safe... 阅读全帖 |
|
K********g
发帖数: 9389 | 43 这个垃圾不碰
Advisory Committee. Adasuve was rejected in October 2010 (under the name AZ-
004) citing adverse pulmonary reactions as well as a required human factors
study to validate the product can be used successfully. Alexza states these
issues are resolved, but the Advisory Committee has stated it will focus on
pulmonary safety. Adasuve may be in the same boat as Mannkind's (MNKD)
Afrezza. Both are novel inhalation powders that have po: ssible pulmonary
reactions. Therefore we will likely see th... 阅读全帖 |
|
b*****h
发帖数: 783 | 44 alxa 是小公司，没长期投资价值。
不过12号的panel 对短期炒作影响很大， 上下50％的幅度吧。
基本就像这个评论写的。
FDA 对它的安全性有疑问。
我感觉fda 态度还可以，而且这个是phase 1 trial 中出现的问题，placebo control
中也有，感觉不会太严重。
不过panel 结论不好预测，risk 挺大的。
Advisory Committee. Adasuve was rejected in October 2010 (under the name AZ-
004) citing adverse pulmonary reactions as well as a required human factors
study to validate the product can be used successfully. Alexza states these
issues are resolved, but the Advisory Committee has stated it will focus on
pulmonary safety. Ada... 阅读全帖 |
|
